Table 7, Strengths and Limitations of Guidelines Using AGREE II - Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update

Item	Greenberg et al. (2021) ³²
Domain 1: scope and purpose
1. The overall objective(s) of the guideline is (are) specifically described.	Yes
2. The health question(s) covered by the guideline is (are) specifically described.	Unclear
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.	Yes
Domain 2: stakeholder involvement
4. The guideline development group includes individuals from all relevant professional groups.	Unclear
5. The views and preferences of the target population (patients, public, etc.) have been sought.	Unclear
6. The target users of the guideline are clearly defined.	Yes
Domain 3: rigour of development
7. Systematic methods were used to search for evidence.	Yes
8. The criteria for selecting the evidence are clearly described.	No
9. The strengths and limitations of the body of evidence are clearly described.	No
10. The methods for formulating the recommendations are clearly described.	No
11. The health benefits, side effects, and risks have been considered in formulating the recommendations.	Unclear
12. There is an explicit link between the recommendations and the supporting evidence.	Yes
13. The guideline has been externally reviewed by experts prior to its publication.	Unclear
14. A procedure for updating the guideline is provided.	No
Domain 4: clarity of presentation
15. The recommendations are specific and unambiguous.	Yes
16. The different options for management of the condition or health issue are clearly presented.	Yes
17. Key recommendations are easily identifiable.	Yes
Domain 5: applicability
18. The guideline describes facilitators and barriers to its application.	No
19. The guideline provides advice and/or tools on how the recommendations can be put into practice.	No
20. The potential resource implications of applying the recommendations have been considered.	No
21. The guideline presents monitoring and/or auditing criteria.	No
Domain 6: editorial independence
22. The views of the funding body have not influenced the content of the guideline.	Unclear
23. Competing interests of guideline development group members have been recorded and addressed.	No

Item

Greenberg et al. (2021) ³²

Domain 1: scope and purpose

1. The overall objective(s) of the guideline is (are) specifically described.

Yes

2. The health question(s) covered by the guideline is (are) specifically described.

Unclear

3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.

Yes

Domain 2: stakeholder involvement

4. The guideline development group includes individuals from all relevant professional groups.

Unclear

5. The views and preferences of the target population (patients, public, etc.) have been sought.

Unclear

6. The target users of the guideline are clearly defined.

Yes

Domain 3: rigour of development

7. Systematic methods were used to search for evidence.

Yes

8. The criteria for selecting the evidence are clearly described.

9. The strengths and limitations of the body of evidence are clearly described.

10. The methods for formulating the recommendations are clearly described.

11. The health benefits, side effects, and risks have been considered in formulating the recommendations.

Unclear

12. There is an explicit link between the recommendations and the supporting evidence.

Yes

13. The guideline has been externally reviewed by experts prior to its publication.

Unclear

14. A procedure for updating the guideline is provided.

Domain 4: clarity of presentation

15. The recommendations are specific and unambiguous.

Yes

16. The different options for management of the condition or health issue are clearly presented.

Yes

17. Key recommendations are easily identifiable.

Yes

Domain 5: applicability

18. The guideline describes facilitators and barriers to its application.

19. The guideline provides advice and/or tools on how the recommendations can be put into practice.

20. The potential resource implications of applying the recommendations have been considered.

21. The guideline presents monitoring and/or auditing criteria.

Domain 6: editorial independence

22. The views of the funding body have not influenced the content of the guideline.

Unclear

23. Competing interests of guideline development group members have been recorded and addressed.

From: Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update

Cover of Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update

Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update: Rapid Review [Internet].

Hill S, Severn M; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 7Strengths and Limitations of Guidelines Using AGREE II14

Table 7Strengths and Limitations of Guidelines Using AGREE II¹⁴